Please check your internet connection and try again.
# Durveqtix gene therapy
## Overview
Durveqtix (fidanocogen elaparvovec-dzzo) is a one-time gene therapy for adult patients with hemophilia B. It delivers a functional copy of the *F9* gene to enable the production of Factor IX (FIX) protein, reducing or eliminating the need for routine FIX prophylaxis.
## Primary Indications
Treatment of hemophilia B (congenital Factor IX deficiency) in adults.
## Adult Dosing
The recommended dose is 1.5 x 10^13 vector genomes per kilogram (vg/kg) administered as a single intravenous infusion.
## Pediatric Dosing
Durveqtix is not approved for pediatric use. Safety and efficacy have not been established.
## Dose Adjustments
No dose adjustments are routinely recommended. The dose is calculated based on body weight for a single administration.
## Contraindications
* Known history of severe allergic reaction to fidanocogen elaparvovec-dzzo, its components, or the drug formulation.
* Active or chronic liver disease (cirrhosis is a contraindication).
## Adverse Effects
The most common adverse reactions (>5% of subjects) observed in clinical trials were:
* Alanine aminotransferase (ALT) elevation
* Headache
* Infusion-related reactions (including pyrexia, chills, fatigue, nausea)
* Aspartate aminotransferase (AST) elevation
* Nausea
* Cough
* Blood creatine kinase elevation
* Dizziness
* Bronchitis
* Rash
* Thrombocytopenia
**Serious adverse events:**
* Hepatotoxicity (ALT/AST elevations)
* Thrombosis (especially in patients with pre-existing risk factors)
* Hypersensitivity/Anaphylaxis
* Development of neutralizing antibodies to AAV5 capsid
## Key Drug Interactions
* **Immunosuppressive therapy:** Concomitant use of immunosuppressants, particularly corticosteroids, may be necessary during the peri-infusion period to mitigate immune responses against the vector or transduced cells. The specific regimen should be guided by local protocol or clinical judgment and can impact the efficacy and safety profile.
* **Hepatotoxic agents:** Caution is advised when co-administering other medications with potential hepatotoxicity due to the risk of elevated liver enzymes.
* **Anticoagulants:** Patients may still require anticoagulation for specific indications beyond hemophilia B management. The interaction of Durveqtix with anticoagulants is not fully characterized, and careful monitoring is recommended.
## Monitoring
* **Liver Function Tests (LFTs):** Frequent monitoring of ALT and AST for at least 6 months post-infusion is crucial to detect and manage potential hepatotoxicity.
* **FIX activity:** Monitor FIX levels to assess the durability of therapeutic effect.
* **Antibody levels:** Monitor for the development of neutralizing antibodies against the AAV5 capsid.
* **Clinical signs and symptoms:** Monitor for signs of hypersensitivity reactions, thrombotic events, or other adverse effects.
## Clinical Pearls
* Durveqtix is a one-time, single-dose infusion.
* Patients with pre-existing FIX inhibitors are not eligible for treatment.
* A thorough risk/benefit assessment is required, especially considering the potential for serious adverse events like hepatotoxicity and thrombosis.
* Management of immune responses (e.g., with corticosteroids) is a critical component of post-infusion care and is often guided by local protocol.
* Lifelong monitoring for potential long-term adverse effects is recommended.
***
*This information is intended for healthcare professionals and does not replace a thorough review of the most current prescribing information or consultation with a specialist. Always verify the latest product monograph and institutional guidelines.*
